D
Daniel Conole
Researcher at University of Auckland
Publications - 21
Citations - 354
Daniel Conole is an academic researcher from University of Auckland. The author has contributed to research in topics: Bedaquiline & Chemistry. The author has an hindex of 9, co-authored 15 publications receiving 272 citations. Previous affiliations of Daniel Conole include Abu Dhabi Indian School.
Papers
More filters
Journal ArticleDOI
Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles.
Hamish S. Sutherland,Amy S.T. Tong,Peter J. Choi,Daniel Conole,Adrian Blaser,Scott G. Franzblau,Christopher B. Cooper,Anna M. Upton,Manisha U. Lotlikar,William A. Denny,Brian D. Palmer +10 more
TL;DR: In this article, the authors replaced the naphthalene C-unit of the anti-tuberculosis drug bedaquiline with a range of bicyclic heterocycles of widely differing lipophilicity.
Journal ArticleDOI
6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis.
Amy S.T. Tong,Peter J. Choi,Adrian Blaser,Hamish S. Sutherland,Sophia K. Y. Tsang,Jerome Emile Georges Guillemont,Magali Madeleine Simone Motte,Christopher B. Cooper,Koen Andries,Walter Van den Broeck,Scott G. Franzblau,Anna M. Upton,William A. Denny,Brian D. Palmer,Daniel Conole +14 more
TL;DR: It is discovered, by virtue of a clogP/M.tb score, that a 6-cyano (CN) substituent provides a substantial reduction in lipophilicity with only modest effects on MIC values, suggesting this substituents as a useful tool in the search for effective and safer analogues of 1.
Journal ArticleDOI
Riociguat: First Global Approval
Daniel Conole,Lesley J. Scott +1 more
TL;DR: Riociguat is the world’s first approved pharmacotherapy for CTEPH, with its first global approval in this indication occurring in Canada and it has subsequently been approved in the USA for the treatment of patients withCTEPH and also received its firstglobal approval in patients with PAH.
Journal ArticleDOI
Colistimethate Sodium Dry Powder for Inhalation: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
Daniel Conole,Gillian M. Keating +1 more
TL;DR: In conclusion, colistimethate sodium DPI administered via the Turbospin® inhaler is a useful option for the treatment of chronic P. aeruginosa infection in patients with CF aged ≥6 years.
Journal ArticleDOI
Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline
Adrian Blaser,Hamish S. Sutherland,Amy S.T. Tong,Peter J. Choi,Daniel Conole,Scott G. Franzblau,Christopher B. Cooper,Anna M. Upton,Manisha U. Lotlikar,William A. Denny,Brian D. Palmer +10 more
TL;DR: The ATP-synthase inhibitor bedaquiline is effective against drug-resistant tuberculosis but is extremely lipophilic (clogP 7.25) with a very long plasma half-life as discussed by the authors.